PA Capital’s Xeris Biopharma Holdings XERS Stock Holding History

PA Capital’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27,420	Closed	-$73K	–	202
2020 Q2	$73K	Buy	+27,420	New	+$95.5K	0.05%	163

Other funds holding XERS

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PA Capital's XERS Position: Q3 2020 in Review

PA Capital sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 27,420 shares — an estimated $73K sold.

PA Capital first reported a position in XERS in Q2 2020 and held it in 1 quarter. The position peaked at $73K in Q2 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

PA Capital reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
PA Capital sold 27,420 Xeris Biopharma Holdings shares in Q3 2020, an estimated $73K.
PA Capital first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 1 quarter.
PA Capital's Xeris Biopharma Holdings position peaked at $73K in Q2 2020.
86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.